https://www.theborneopost.com/2020/08/30/vying-for-vaccines/
US’ Generex signs agreement with Malaysia’s Bintai Kinden
Generex Biotechnology Corporation on August 18 announced that the company has signed a memorandum of understanding with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Covid-19 vaccine.
The vaccine is designed as a “Complete Vaccine” that has the potential to induce the T-Cell and antibody immune responses that can provide protective immunity with long-lasting immunologic memory against Covid-19 in a highly specific manner to ensure safety.
With this agreement, Bintai has agreed to pay Generex up-front development fees and back-end licensing payments, and will pay 100 per cent of the funding required for the commercial development of the vaccine including laboratory work, manufacturing, regulatory filings and the clinical development program for regulatory approval of the vaccine in Malaysia.
Additionally, upon approval of the Ii-Key-CoV-2 vaccine in Malaysia, Generex will earn royalties on sales of the vaccine with potential revenues of up to US$150 million.
Bintai and Generex agree that the vaccine manufacturing should serve not only as an essential element of a vaccination program for each country, but also as an economic stimulus, as many countries shift their focus to rebuild their economies following the inevitable economic shutdown as the battle of the global pandemic continues.
Generex chief executive officer Joseph Moscato in a statement said, “We are excited and proud to have Bintai as a partner to develop our Ii-Key-SARS-CoV-2 vaccine against Covid-19. Our ‘complete vaccine’ has the potential to generate both a cellular (T-Cell) and humoral (antibody) response to ensure immune system memory and long-term immunity from Covid-19.
“Our partners in Malaysia have recognised the true potential of the Ii-Key technology to activate the T-Cell response as part of any successful coronavirus vaccine that enables long-term immunity.
“Further, our proprietary vaccine development process is designed using computational vaccinology and immune system screening program to identify specific target regions of the SARS-CoV-2 spike protein that can neutralise the virus without generating the off-target effects that lead to the terrible complications of Covid-19.
“This deal also leverages Bintai’s expertise in industrial engineering and construction to provide the manufacturing capability that can produce the billions of doses of vaccine that will be necessary to immunise a global population
US’ Generex signs agreement with Malaysia’s Bintai Kinden
Generex Biotechnology Corporation on August 18 announced that the company has signed a memorandum of understanding with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Covid-19 vaccine.
The vaccine is designed as a “Complete Vaccine” that has the potential to induce the T-Cell and antibody immune responses that can provide protective immunity with long-lasting immunologic memory against Covid-19 in a highly specific manner to ensure safety.
With this agreement, Bintai has agreed to pay Generex up-front development fees and back-end licensing payments, and will pay 100 per cent of the funding required for the commercial development of the vaccine including laboratory work, manufacturing, regulatory filings and the clinical development program for regulatory approval of the vaccine in Malaysia.
Additionally, upon approval of the Ii-Key-CoV-2 vaccine in Malaysia, Generex will earn royalties on sales of the vaccine with potential revenues of up to US$150 million.
Bintai and Generex agree that the vaccine manufacturing should serve not only as an essential element of a vaccination program for each country, but also as an economic stimulus, as many countries shift their focus to rebuild their economies following the inevitable economic shutdown as the battle of the global pandemic continues.
Generex chief executive officer Joseph Moscato in a statement said, “We are excited and proud to have Bintai as a partner to develop our Ii-Key-SARS-CoV-2 vaccine against Covid-19. Our ‘complete vaccine’ has the potential to generate both a cellular (T-Cell) and humoral (antibody) response to ensure immune system memory and long-term immunity from Covid-19.
“Our partners in Malaysia have recognised the true potential of the Ii-Key technology to activate the T-Cell response as part of any successful coronavirus vaccine that enables long-term immunity.
“Further, our proprietary vaccine development process is designed using computational vaccinology and immune system screening program to identify specific target regions of the SARS-CoV-2 spike protein that can neutralise the virus without generating the off-target effects that lead to the terrible complications of Covid-19.
“This deal also leverages Bintai’s expertise in industrial engineering and construction to provide the manufacturing capability that can produce the billions of doses of vaccine that will be necessary to immunise a global population
2
